涉嫌内幕交易等被立案 贵州百灵董事长姜伟连夜发全员信：恳请员工“坚守岗位”！

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. announced that its actual controller, Jiang Wei, is under investigation by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, which is unrelated to the company's daily operations and will not affect its business activities [2][18]. Group 1: Investigation and Company Response - Jiang Wei, the chairman of Guizhou BaiLing, is being investigated for insider trading and related violations, and he will cooperate with the CSRC during the investigation [2][20]. - The company reassured stakeholders that the investigation pertains solely to Jiang Wei and will not impact the company's operations or management [2][18]. - Jiang Wei sent a letter to employees urging them to remain focused on their work and not to worry excessively about the situation, emphasizing the importance of maintaining productivity [20][19]. Group 2: Financial and Legal Context - Jiang Wei is involved in a legal dispute with Huachuang Securities regarding a financial rescue plan and stock pledge disputes, with the total amount in question reaching 1.761 billion yuan, including principal and related fees [7][24]. - Since 2018, Jiang Wei has faced financial difficulties due to heavy debt burdens and declining stock prices, leading to a significant increase in stock pledge ratios [8][25]. - As of the third quarter, Jiang Wei held 245 million shares of Guizhou BaiLing, representing a 17.55% stake, all of which are pledged [12][29]. Group 3: Company Financial Performance - Guizhou BaiLing reported a third-quarter revenue of 640 million yuan, a year-on-year increase of 1.11%, while the net profit attributable to shareholders was 4.98 million yuan, up 559.90% [15][32]. - For the first three quarters, the company's revenue was 2.102 billion yuan, a decrease of 24.28%, with a net profit of 56.81 million yuan, down 35.60% [15][32]. - The company's stock price closed at 5.57 yuan on December 3, reflecting a year-to-date increase of over 44% [16][33].